🟢 Moleculin Biotech is trading 5% up today after Q2 results and MIRACLE trial progress

Moleculin Biotech is trading 5.01% up at $0.60 after second-quarter 2026 results and MIRACLE progress.

• Preliminary results from 45 patients showed complete remission rates at least three times higher than the control arm; enrollment for 90 patients in September remains on track.
• Cash and financing proceeds are expected to fund operations into Q1 2027.
• A company-specific catalyst, though no source quantified its trading effect; shares continued advancing from $0.39 on August 5 to $0.57 on August 13.